Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Primary Care
How often do you offer repeat imaging for patients with life expectancy>10 years and BCR prostate cancer with PSADT>10 months while they are on observation?
Related Questions
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
How do you manage recurrent asymptomatic transaminitis from VEGF TKI in a patient renal cell carcinoma who needs drug to control disease?
How would you approach patients with high-risk localized prostate cancer (per STAMPEDE criteria) receiving RT and concurrent ADT but are unable to tolerate abiraterone secondary to toxicities?
Would you be more inclined to offer adjuvant therapy to a patient who is age>60 with stage 1B seminoma?
How do you manage critically ill poor risk mixed germ cell tumor patients presenting de novo with extensive lung metastases and severe respiratory failure?
In which patients are referring for focal gland therapy for localized prostate cancer?
